Apparent efficacy and safety of low dose naltrexone in Australian patients with active Crohn's disease

J Gastroenterology and Hepatology
October 2013
https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgh.12365_6

Open label and randomised controlled trial evidence indicates that low dose naltrexone (LDN), a strong opioid antagonist, has efficacy in reducing inflammatory activity in patients with Crohn’s disease. All evidence has come from one institution. 

P-015 YI Low-Dose Naltrexone Therapy Improves Active Ulcerative Colitis

Inflam Bowel Dis
01 December 2013
https://academic.oup.com/ibdjournal/search-results?page=1&q=Low-Dose%20Naltrexone%20Therapy%20Improves%20Active%20Ulcerative%20Colitis&fl_SiteID=6136&SearchSourceType=1&allJournals=1

Tu1365 Low Dose Naltrexone in the Treatment of Crohn's Disease: A Case Series

Gastroenterology
April 2015
http://www.gastrojournal.org/article/S0016-5085(15)32952-8/abstract

Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial

Dig Dis Sci
July 2011
https://pubmed.ncbi.nlm.nih.gov/21380937/ 

Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient

Inflamm Bowel Dis
September 2010
https://academic.oup.com/ibdjournal/article/16/9/1457/4628412

Low-dose naltrexone therapy improves active Crohn's disease

Am J Gastroenterol
April 2007
https://pubmed.ncbi.nlm.nih.gov/17222320/

Objectives: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease.

Psychoneuroimmunological approach to gastrointestinal related pain

Scand J Pain
October 2017
https://pubmed.ncbi.nlm.nih.gov/29122501/

The Use of Naltrexone in Low Doses Beyond the Approved Indication [Internet]

Report from Norwegian Knowledge Centre for the Health Services
April 2015
https://pubmed.ncbi.nlm.nih.gov/28510411/

The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders

Pharmacotherapy
March 2018
https://pubmed.ncbi.nlm.nih.gov/29377216/

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

J Transl Med
09 March 2018
https://pubmed.ncbi.nlm.nih.gov/29523156/